AbbVie Inc.(ABBV)Earnings, Financials & Key RatiosAbbVie Inc. (ABBV) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the company demonstrates strong cash generation with a 23.8% FCF margin in 2026Q1, the high debt-to-equity ratio of 2.65 and significant goodwill concentration of $35.6 billion warrant a cautious approach.
AbbVie Inc. (ABBV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
AbbVie Inc. (ABBV) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $2.65vs $2.59+2.3% | $15.0Bvs $14.7B+1.9% |
| Q1 2026 | Feb 4, 2026 | $2.71vs $2.65+2.3% | $16.6Bvs $16.4B+1.2% |
| Q4 2025 | Oct 31, 2025 | $1.86vs $1.77+5.1% | $15.8Bvs $15.6B+1.2% |
| Q3 2025 | Jul 31, 2025 | $2.97vs $2.88+3.1% | $15.4Bvs $15.0B+2.6% |
Recent stock market news and headlines for AbbVie Inc. (ABBV)
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQÂ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary endpoints, including improvements in eyebrows and eyelashes, at week 24 1,2 Upadacitinib is the first JAK inhibitor to meet the stringent ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24 1,2 NORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA).
If approved, upadacitinib is expected to be the first systemic medication for patients with non-segmental vitiligo, addressing important treatment needs for those living with the chronic, unpredictable autoimmune disease Positive CHMP opinion is supported by data from the Phase 3 Viti-Up clinical studies, in which upadacitinib achieved both co-primary endpoints demonstrating at least a 50% improvement in total body repigmentation (T-VASI 50) and at least a 75% improvement in facial repigmentation (F-VASI 75) from baseline at week 48 1 NORTH CHICAGO, Ill., June 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg, once daily) for the treatment of adult and adolescent patients with non-segmental vitiligo (NSV).
SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a new 55 mg pre-filled syringe to support weight-based dosing for those patients weighing less than 40 kg SKYRIZI becomes the first and only IL-23 inhibitor approved in the U.S. for pediatric patients six years of age and older weighing less than 40 kg with plaque psoriasis or psoriatic arthritis NORTH CHICAGO, Ill., June 26, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, or active psoriatic arthritis.
Healthcare stocks outperformed the broader market on Friday, with Eli Lilly (LLY), Johnson and Johnson (JNJ) and AbbVie (ABBV) among the major names hitting fresh
Key metrics vs top competitors for AbbVie Inc. (ABBV)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $254.65 | $449.91B | 107.45 | 8.57% | 6.91% | 6214.71% | 2.58% | |
| $267.24 | $643.31B | 24.23 | 6.05% | 21.83% | 26.26% | — | |
| $128.86 | $318.26B | 17.70 | 1.18% | 13.62% | 17.91% | — | |
| $24.07 | $136.92B | 17.70 | -1.65% | 11.83% | 8.34% | — | |
| $57.97 | $118.36B | 16.80 | -0.22% | 15.01% | 38.96% | — | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — |
AbbVie Inc. (ABBV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AbbVie Inc. (ABBV) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 22, 2026·SEC
May 12, 2026·SEC
Apr 29, 2026·SEC
Get notified when ABBV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AbbVie Inc. (ABBV) stock FAQ — growth, dividends, profitability & financials explained
AbbVie Inc. (ABBV) reported $62.82B in revenue for fiscal year 2025. This represents a 302% increase from $15.64B in 2010.
AbbVie Inc. (ABBV) grew revenue by 8.6% over the past year. This is steady growth.
Yes, AbbVie Inc. (ABBV) is profitable, generating $3.64B in net income for fiscal year 2025 (6.9% net margin).
Yes, AbbVie Inc. (ABBV) pays a dividend with a yield of 2.58%. This makes it attractive for income-focused investors.
AbbVie Inc. (ABBV) has a return on equity (ROE) of 6214.7%. This is excellent, indicating efficient use of shareholder capital.
AbbVie Inc. (ABBV) generated $20.86B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
